STOCKHOLM, Sweden, Aug. 27, 2004 (PRIMEZONE) -- Highlights of Artimplant AB's Interim Report January 1 - JUNE 30, 2004:
Increased Sales Efforts and Continued Strong Cash Position
- Artimplant's net sales for the 6 month period reached SEK 1.0 million (SEK 1.2 million) - Losses after tax amounted to SEK --13.3 million (SEK --11.2 million) - The result per share amounted to SEK --0.35 (SEK --0.52) - Liquid funds at the end of the period amounted to SEK 63.8 million - Artelon TMC Spacer marketing activities have commenced in the Nordic countries
Developments After the End of the Period
- The test sales of Artelon ACL Augmentation Device in the United Kingdom has expired
For more information, contact: Tord Lendau, CEO, +46 31 746 5600, +46 708 369 403, tord.lendau@artimplant.se Jonas Strom, CFO, +46 31 746 5654, +46 703 016 854, jonas.strom@artimplant.se
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2004/08/27/20040827BIT20280/wkr0001.pdf The full report